Bardoxolone Methyl Use in Alport Syndrome With Patient Risk Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There are limited treatment options for Alport syndrome, a rare hereditary disease causing glomerular filtration rate decline and leading to end-stage renal disease, with existing treatments like bardoxolone methyl showing adverse effects in certain patient populations.
Innovation Solution
Administer bardoxolone methyl or its analogues in specific patient populations, excluding those with endothelial dysfunction risk factors, to treat or prevent Alport syndrome by improving kidney function and reducing inflammation and fibrosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bardoxolone methyl is administered to treat Alport syndrome, then kidney function is improved and inflammation is reduced, but the complexity of treatment formulation and administration increases
Solution Approach 1:
The patent utilizes different polymorphic forms (Form A crystalline, Form B amorphous/glassy) of bardoxolone methyl with distinct physical parameters (X-ray diffraction patterns, glass transition temperatures) to optimize drug delivery and efficacy while managing formulation complexity
Solution Approach 2:
The patent employs composite formulation approaches by combining bardoxolone methyl with various excipients and delivery systems (liposomes, emulsions, solid dispersions) to enhance therapeutic effect while systematically managing the complexity of treatment administration
2Duration of action of stationary object
If bardoxolone methyl treatment is implemented, then progression of kidney damage is slowed, but the availability of effective treatment options remains limited
Solution Approach 1:
The patent positions bardoxolone methyl as a multi-functional therapeutic agent that addresses multiple aspects of Alport syndrome pathophysiology simultaneously: reducing oxidative stress, inhibiting pro-inflammatory signaling pathways, and preventing fibrosis, thereby providing a versatile treatment option for this condition
3Object-affected harmful factors
If bardoxolone methyl is used to inhibit pro-fibrotic signaling pathways, then fibrosis is reduced, but the mechanism of action becomes more complex
Solution Approach 1:
The patent focuses on extracting and targeting specific pro-fibrotic signaling pathways (TGF-β, CTGF, endothelin-1) among the multiple pathways affected by bardoxolone methyl, thereby simplifying the understanding and monitoring of the drug's anti-fibrotic mechanism while maintaining comprehensive therapeutic effect
Data Source
Figure 1A~1C
Figure 2
Figure 3A
AI summary
The present invention provides methods of treating or preventing Alport syndrome in a patients in need thereof using bardoxolone methyl or analogs thereof, and/or improving the kidney function of patients who have been diagnosed with Alport syndrome.